Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD 13.95
+0.26 (1.90%)
Jul 24, 2026, 3:55 PM EST
Satellos Bioscience Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
290.60M CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSatellos Bioscience News
- 15 days ago - Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - MarketBeat
- 17 days ago - Satellos Bioscience Inc TRAILHEAD Study Data Update Call Transcript - GuruFocus
- 18 days ago - Satellos Bioscience Transcript: Study update - Transcripts
- 18 days ago - Satellos Bioscience Press release: Study update - Filings
- 18 days ago - Satellos Bioscience Slides: Study update - Filings
- 18 days ago - Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 - GlobeNewsWire
- 19 days ago - Satellos Bioscience Slides: Corporate presentation - Filings
- 26 days ago - Satellos' SAT-3247 Wins FDA Fast Track Status For Duchenne Muscular Dystrophy, Stock Up - Nasdaq